Julie Fleshman, president and CEO of the Pancreatic Cancer Action Network, sent a letter to Congress in response to the proposed NIH budget cuts.
UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.
